[1]孟倩丽,张良,谢洁.几种糖尿病相关眼病的诊断治疗规范[J].眼科新进展,2022,42(4):253-261.[doi:10.13389/j.cnki.rao.2022.0052]
　MENG Qianli,ZHANG Liang,XIE Jie.Diagnosis and treatment of several diabetes-related eye diseases[J].Recent Advances in Ophthalmology,2022,42(4):253-261.[doi:10.13389/j.cnki.rao.2022.0052]
点击复制

几种糖尿病相关眼病的诊断治疗规范/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
42卷
期数:
2022年4期
页码:
253-261
栏目:
述评
出版日期:
2022-04-05

文章信息/Info

Title:
Diagnosis and treatment of several diabetes-related eye diseases
作者:
孟倩丽; 张良; 谢洁
510080　广东省广州市，广东省人民医院（广东省医学科学院）眼科，广东省眼病防治研究所
Author(s):
MENG Qianli; ZHANG Liang; XIE Jie
Department of Ophthalmology,Guangdong Eye Institute,Guangdong Provincial People’s Hospital,Guangdong Academy of Medical Sciences,Guangzhou 510080,Guangdong Province,China
关键词:
糖尿病性视网膜病变; 糖尿病性视神经病变; 糖尿病性白内障; 糖尿病相关眼表疾病; 糖尿病性眼肌麻痹
Keywords:
diabetic retinopathy;  diabetic optic neuropathy;  diabetic cataract;  diabetes-related ocular surface disease;  diabetic ophthalmoplegia
分类号:
R771.3
DOI:
10.13389/j.cnki.rao.2022.0052
文献标志码:
A
摘要:
糖尿病是全身糖代谢紊乱所导致的慢性炎症性疾病，目前仍然是全球严重的公共卫生问题。作为重要糖尿病靶器官损害之一，糖尿病眼部并发症是一组严重影响患者视觉质量乃至致盲的眼病。常见的糖尿病相关眼病包括糖尿病性视网膜病变、糖尿病性视神经病变、糖尿病性白内障、糖尿病相关眼表疾病、糖尿病性眼肌麻痹等，其规范化管理需要多学科密切合作。本文就糖尿病相关眼病的诊断标准和治疗规范进行总结，以期加强对此类疾病的认识与综合管理。
Abstract:
Diabetes mellitus is a chronic inflammatory disease caused by disorder of systemic glucose metabolism, and it is still a serious public health problem worldwide. As one of the important diabetic target organ damages, diabetic eye complications seriously affect visual quality and even cause blindness. Common diabetes-related eye diseases include diabetic retinopathy, diabetic optic neuropathy, diabetic cataract, diabetes-related ocular surface disease, and diabetic ophthalmoplegia. The standardized management of these diseases requires close multidisciplinary cooperation. This article summarizes the diagnostic criteria and treatment norms of diabetes-related eye diseases, in order to strengthen the understanding and comprehensive management of these diseases.

参考文献/References:

［1］　SAEEDI P,INGA P,PARASKEVI S,BELMA M,SUVI K,UNWIN N,et al.Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045:results from the International Diabetes Federation Diabetes Atlas,9th edition［J］.Diabetes Res Clin Pract,2019,157:107843.
［2］　中国老年2型糖尿病防治临床指南编写组,中国老年医学学会老年内分泌代谢分会,中国老年保健医学研究会老年内分泌与代谢分会,北京医学奖励基金会老年医学专业委员会,国家老年疾病临床医学研究中心(解放军总医院).中国2型糖尿病防治指南(2020年版)［J］.中华内分泌代谢杂志,2021,37(4):311-398.
China’s Clinical Guidelines for the Prevention and Treatment of Type 2 Diabetes in the Elderly, Endocrine and Metabolism Branch of China Geriatrics Society, GERiatric Endocrinology and Metabolism Branch of China Geriatric Health Care Research Association,Geriatrics Specialized Committee of Beijing Medical Award Foundation,National Geriatric Disease Clinical Research Center (PLA General Hospital).Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)［J］.Chin J Endocrinol Metabol,2021,37(4):311-398.
［3］　LI Y,TENG D,SHI X G,QIN G,QIN Y,QUAN H,et al.Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association:National cross sectional study［J］.BMJ,2020,369:m997.
［4］　WANG L,GAO P,ZHANG M,HUANG Z,ZHANG D,DENG Q,et al.Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013［J］.JAMA,2017,317(24):2515-2523.
［5］　YAU J W,ROGERS S L,KAWASAKI R,LAMOUREUX E L,KOWALSKI J W,BEK T,et al.Global prevalence and major risk factors of diabetic retinopathy［J］.Diabetes Care,2012,35(3):556-564.
［6］　TING D S,CHEUNG G C,WONG T Y.Diabetic retinopathy:global prevalence,major risk factors,screening practices and public health challenges:a review［J］.Clin Exp Ophthalmol,2016,44(4):260-277.
［7］　VARMA R,BRESSLER N M,DOAN Q V,GLEESON M,DANESE M,BOWER J K,et al.Prevalence of and risk factors for diabetic macular edema in the United States［J］.JAMA Ophthalmol,2014,132(11):1334-1340.
［8］　SONG P,YU J,CHAN K Y,THEODORATOU E,RUDAN I.Prevalence,risk factors and burden of diabetic retinopathy in China:a systematic review and meta-analysis［J］.J Glob Health,2018,8(1):010803.
［9］　JONES C D,GREENWOOD R H,MISRA A,BACHMANN M.Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England［J］.Diabetes Care,2012,35(3):592-596.
［10］　WEST S K,KLEIN R,RODRIGUEZ J,MUOZ B,BROMAN A T,SANCHEZ R,et al.Diabetes and diabetic retinopathy in a Mexican-American population:proyecto VER［J］.Diabetes Care,2001,24(7):1204-1209.
［11］　李晓莉,孟倩丽,谢洁,陈湘婷,黄天.新型眼底影像检查技术在糖尿病视网膜病变诊断中的应用［J］.中华眼底病杂志,2019,35(1):90-94.
LI X L,MENG Q L,XIE J,CHEN X T,HUANG T.Application of new fundus imaging in diagnosis of diabetic retinopathy［J］.Chin J Ocul Fundus Dis,2019,35(1):90-94.
［12］　LI X,XIE J,ZHANG L,CUI Y， MENG Q.Identifying microvascular and neural parameters related to the severity of diabetic retinopathy using optical coherence tomography angiography［J］.Invest Ophthalmol Vis Sci,2020,61(5):39.
［13］　YANNUZZI L A,OBER M D,SLAKTER J S,SPAIDE R F,FISHER Y L,FLOWER R W,et al.Ophthalmic fundus imaging:today and beyond［J］.Am J Ophthalmol,2004,137(3):511-524.
［14］　HUTCHINSON A,MCINTOSH A,PETERS J,O’KEEFFE C,KHUNTI K,BAKER R,et al.Effectiveness of screening and monitoring tests for diabetic retinopathy:a systematic review［J］.Diabet Med,2000,17(7):495-506.
［15］　SILVA P S,CAVALLERANO J D,TOLLS D.Potential efficiency benefits of nonmydriatic ultrawide field retinal imaging in an ocular telehealth diabetic retinopathy program［J］.Diabetes Care,2014,37(1):50-55.
［16］　中华医学会糖尿病学分会视网膜病变学组.糖尿病相关眼病防治多学科中国专家共识（2021年版）［J］.中华糖尿病杂志,2021,13(11):1026-1042.
Retinopathy Group of Diabetes Association, Chinese Medical Association.China consensus on multidisciplinary prevention and treatment of diabetic eye diseases (2021 Edition) ［J］.Chin J Diabetes,2021,13(11):1026-1042.
［17］　中国医药教育协会智能医学专委会智能眼科学组,国家重点研发计划“眼科多模态成像及人工智能诊疗系统的研发和应用”项目组.基于眼底照相的糖尿病视网膜病变人工智能筛查系统应用指南［J］.中华实验眼科杂志,2019,37(8):593-598.
Intelligent Ophthalmology Group of Intelligent Medicine Special Committee of China Medical Education Association,Project Group of National Key Research and Development Plan “Research and Application of Ophthalmic Multimodal Imaging and Artificial Intelligence Diagnosis and Treatment System”.Application guide of artificial intelligence screening system for diabetic retinopathy based on fundus photography［J］.Chin J Exp Ophthalmol,2019,37(8):593-598.
［18］　FLAXEL C J,ADELMAN R A,BAILEY S T,FAWZI A,LIM J I,VEMULAKONDA G A,et al.Diabetic retinopathy preferred practice pattern?［J］.Ophthalmology,2020,127(1):66-145.
［19］　LU J,MA X,ZHOU J,ZHANG L,MO Y,YING L,et al.Association of time in range,as assessed by continuous glucose monitoring,with diabetic retinopathy in type 2 diabetes［J］.Diabetes Care,2018,41(11):2370-2376.
［20］　MERANTE D,MENCHINI F,TRUITT K,BANDELLO F M.Diabetic macular edema:correlations with available diabetes therapies:evidence across a qualitative review of published literature from MEDLINE and EMBASE［J］.Drug Saf,2010,33(8):643-652.
［21］　KEECH A C,MITCHELL P,SUMMANEN P A,O’DAY J,DAVIS T M,MOFFITT M S,et al.Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study):a randomised controlled trial［J］.Lancet,2007,370(960):1687-1697.
［22］　ACCORD Study Group,ACCORD Eye Study Group,CHEW E Y,AMBROSIUS W T,DAVIS M D,DANIS R P,et al.Effects of medical therapies on retinopathy progression in type 2 diabetes［J］.N Engl J Med,2010,363(3):233-244.
［23］　NOONAN J E,JENKINS A J,MA J X,KEECH A C,WANG J J,LAMOUREUX E L.An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes［J］.Diabetes,2013,62(12):3968-3975.
［24］　Early Treatment Diabetic Retinopathy Study Research Group.Photocoagulation for diabetic macular edema.Early treatment diabetic retinopathy study report number 1 ［J］.Arch Ophthalmol,1985,103(12):1796-1806.
［25］　WM A,GHANCHI F,BAILEY C,BANERJEE S,BANERJEE SAD-EYE CLINIC U H,DOWNEY L,et al.Diabetic retinopathy and diabetic macular oedema pathways and management:UK Consensus Working Group［J］.Eye (Lond),2020,34(Suppl 1):1-51.
［26］　中华医学会眼科学会眼底病学组.我国糖尿病视网膜病变临床诊疗指南(2014年)［J］.中华眼科杂志,2014,50(11):851-865.
Ophthalmology Group of Chinese Medical Association.Guideline for clinical diagnosis and treatment of diabetic retinopathy in China (2014) ［J］.Chin J Ophthalmol,2014,50(11):851-865.
［27］　BRESSLER S B,AYALA A R,BRESSLER N M,MELIA M,QIN H,FERRIS F,et al.Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment［J］.JAMA Ophthalmol,2016,134(3):278-285.
［28］　GONZALEZ V H,CAMPBELL J,HOLEKAMP N M,KISS S,LOEWENSTEIN A,AUGUSTIN A J,et al.Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema:analysis of protocol I data［J］.Am J Ophthalmol,2016,172:72-79.
［29］　BRESSLER N M,BEAULIEU W T,GLASSMAN A R,BLINDER K J,BRESSLER S B,JAMPOL L M,et al.Persistent macular thickening following intravitreous aflibercept,bevacizumab,or ranibizumab for central-involved diabetic macular edema with vision impairment:a secondary analysis of a randomized clinical trial［J］.JAMA Ophthalmol,2018,136(3):257-269.
［30］　BOYER D S,YOON Y H,BELFORT R,BANDELLO F,MATURI R K,AUGUSTIN A J,et al.Three-year,randomized,sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema［J］.Ophthalmology,2014,121(10):1904-1914.
［31］　ROSENBLATT A,UDAONDO P,CUNHA-VAZ J,SIVAPRASAD S,BANDELLO F,LANZETTA P,et al.A collaborative retrospective study on the efficacy and safety of intravitreal dexamethasone implant (ozurdex) in patients with diabetic macular edema:the European DME registry study［J］.Ophthalmology,2020,127(3):377-393.
［32］　Diabetic Retinopathy Clinical Research Network,ELMAN M J,QIN H,AIELLO L P,BECK R W,BRESSLER N M,et al.Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment:three-year randomized trial results［J］.Ophthalmology,2012,119(11):2312-2318.
［33］　RAJENDRAM R,FRASER-BELL S,KAINES A,MICHAELIDES M,HAMILTON R D,ESPOSTI S D,et al.A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema:24-month data:report 3［J］.Arch Ophthalmol,2012,130(8):972-979.
［34］　RéGNIER S,MALCOLM W,ALLEN F,WRIGHT J,BEZLYAK V.Efficacy of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema:a systematic review and network meta-analysis［J］.PLoS One,2014,9(7):e102309.
［35］　Diabetic Retinopathy Clinical Research Network,ELMAN M J,AIELLO L P,BECK R W,BRESSLER N M,BRESSLER S B,et al.Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema［J］.Ophthalmology,2010,117(6):1064-1077.
［36］　汪婷丽,周怀蔚,殷心轩,李志清.阈下微脉冲激光在糖尿病黄斑水肿中作用机制的研究进展［J］.中华眼底病杂志,2021,37(1):73-77.
WANG T L,ZHOU H W,YIN X X,LI Z Q.Research advances in the mechanism of subthreshold micropulse laser in diabetic macular edema［J］.Chin J Ocul Fundus Dis,2021,37(1):73-77.
［37］　LUTTRULL J K,DORIN G.Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema:a review［J］.Curr Diabetes Rev,2012,8(4):274-284.
［38］　VUJOSEVIC S,MARTINI F,CONVENTO E,LONGHIN E,KOTSAFTI O,PARROZZANI R,et al.Subthreshold laser therapy for diabetic macular edema:metabolic and safety issues［J］.Curr Med Chem,2013,20(26):3267-3271.
［39］　ZHAO X Y,XIA S,CHEN Y X.Antivascular endothelial growth factor agents pretreatment before vitrectomy for complicated proliferative diabetic retinopathy:a meta-analysis of randomised controlled trials［J］.Br J Ophthalmol,2018,102(8):1077-1085.
［40］　SIMUNOVIC M P,MABERLEY D A.Anti-vascular endothelial growth factor therapy for proliferative diabetic retinopathy a systematic review and meta-analysis［J］.Retina (Philadelphia,Pa.),2015,35(10):1931-1942.
［41］　SMITH J M,STEEL D H.Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy［J］.Cochrane Database Syst Rev,2015(8):CD008214.
［42］　TAKAMURA Y,SHIMURA M,KATOME T,SOMEYA H,SUGIMOTO M,HIRANO T,et al.Effect of intravitreal triamcinolone acetonide injection at the end of vitrectomy for vitreous haemorrhage related to proliferative diabetic retinopathy［J］.Br J Ophthalmol,2018,102(10):1351-1357.
［43］　LIAO M,HUANG Y,WANG J,MENG X,LIU Y,YU J,et al.Long-term outcomes of administration of intravitreal triamcinolone acetonide after posterior vitreous detachment during pars plana vitrectomy for proliferative diabetic retinopathy［J］.Br J Ophthalmol,2021.［Online ahead of print］.
［44］　SIM R,HERNNDEZ C,European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR).Neurodegeneration is an early event in diabetic retinopathy:therapeutic implications［J］.Br J Ophthalmol,2012,96(10):1285-1290.
［45］　STEM M S,GARDNER T W.Neurodegeneration in the pathogenesis of diabetic retinopathy:molecular mechanisms and therapeutic implications［J］.Curr Med Chem,2013,20(26):3241-3250.
［46］　SOHN E H,VAN DIJK H W,JIAO C,KOK P H,JEONG W,DEMIRKAYA N,et al.Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus［J］.Proc Natl Acad Sci U S A,2016,113(19):E2655-E2664.
［47］　LI J B,WANG C Y,CHEN J W,LI X L,FENG Z Q,MA H T.The preventive efficacy of methylcobalamin on rat peripheral neuropathy influenced by diabetes via neural IGF-1 levels［J］.Nutr Neurosci,2010,13(2):79-86.
［48］　张良,胡洁,曹丹.糖尿病眼病临床防治［M］.广州:广东科技出版社,2020.
ZHANG L,HU J,CAO D.Clinical prevention and treatment of diabetic ophthalmopathy［M］.Guangzhou:Guangdong Science & Technology Press,2020.
［49］　HAYREH S S,JOOS K M,PODHAJSKY P A,LONG C R.Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy［J］.Am J Ophthalmol,1994,118(6):766-780.
［50］　中华医学会眼科学分会神经眼科学组,中国医药教育协会眼科专业委员会,复方樟柳碱临床应用专家共识专家组.复方樟柳碱注射液在常见缺血性眼病中应用专家共识(2020版)［J］.中华实验眼科杂志,2020,38(7):553-561.
Neuroophthalmology Group of Ophthalmology Branch of Chinese Medical Association, Ophthalmology Professional Committee of Chinese Medical Education Association, Consensus Expert Group of Clinical Application of Compound Anisodine.Chinese experts consensus on compound anisodine injection in the ischemic ophthalmopathy clinical practice (2020)［J］.Chin J Exp Ophthalmol,2020,38(7):553-561.
［51］　OSTRI C,LUND-ANDERSEN H,SANDER B,HVIDT-NIELSEN D,LARSEN M.Bilateral diabetic papillopathy and metabolic control［J］.Ophthalmology,2010,117(11):2214-2217.
［52］　MANSOUR A M,EL-DAIRI M A,SHEHAB M A,SHAHIN H K,SHAABAN J A,ANTONIOS S R.Periocular corticosteroids in diabetic papillopathy［J］.Eye (Lond),2005,19(1):45-51.
［53］　WILLERSLEV A,MUNCH I C,LARSEN M.Resolution of diabetic papillopathy after a single intravitreal injection of ranibizumab［J］.Acta Ophthalmol,2012,90(5):e407-409.
［54］　CHIN E K,ALMEIDA D R,SOHN E H.Sustained and expedited resolution of diabetic papillopathy with combined PRP and bevacizumab［J］.Can J Ophthalmol,2015,50(5):e88-91.
［55］　LI L,WAN X H,ZHAO G H.Meta-analysis of the risk of cataract in type 2 diabetes［J］.BMC Ophthalmol,2014,14:94.
［56］　OBROSOVA I G,CHUNG S S,KADOR P F.Diabetic cataracts:mechanisms and management［J］.Diabetes Metab Res Rev,2010,26(3):172-180.
［57］　PINARCI E Y,BAYAR S,SIZMAZ S,YESILIRMAK N,AKKOYUN I,YILMAZ G.Anterior segment complications after phacovitrectomy in diabetic and nondiabetic patients［J］.Eur J Ophthalmol,2013,23(2):223-229.
［58］　GREENBERG P B,TSENG V L,WU W C,LIU J,JIANG L,CHEN C K,et al.Prevalence and predictors of ocular complications associated with cataract surgery in United States veterans［J］.Ophthalmology,2011,118(3):507-514.
［59］　中华医学会眼科学分会白内障及人工晶状体学组.中国糖尿病患者白内障围手术期管理策略专家共识（2020年）［J］.中华眼科杂志,2020,56(5):337-342.
Cataract and Intraocular Lens Group,Ophthalmology Branch,Chinese Medical Association.Expert consensus on perioperative management strategy for cataract in China’s diabetic patients (2020) ［J］.Chin J Ophthalmol,2020,56(5):337-342.
［60］　YLINEN P,LAINE I,LINDHOLM J M,TUUMINEN R.Poor glycemic control as a risk factor for pseudophakic cystoid macular edema in patients with diabetes［J］.J Cataract Refract Surg,2017,43(11):1376-1382.
［61］　SUTO C,HORI S,KATO S,MURAOKA K,KITANO S.Effect of perioperative glycemic control in progression of diabetic retinopathy and maculopathy［J］.Arch Ophthalmol,2006,124(1):38-45.
［62］　MARKOULLI M,FLANAGAN J,TUMMANAPALLI S S,WU J,WILLCOX M.The impact of diabetes on corneal nerve morphology and ocular surface integrity［J］.Ocul Surf,2018,16(1):45-57.
［63］　DOGRU M,KATAKAMI C,INOUE M.Tear function and ocular surface changes in noninsulin-dependent diabetes mellitus［J］.Ophthalmology,2001,108(3):586-592.
［64］　ALVES M,CALEGARI V C,CUNHA D A,SAAD M J,VELLOSO L A,ROCHA E M.Increased expression of advanced glycation end-products and their receptor,and activation of nuclear factor kappa-B in lacrimal glands of diabetic rats［J］.Diabetologia,2005,48(12):2675-2681.
［65］　JAFFE G J,BURTON T C.Progression of nonproliferative diabetic retinopathy following cataract extraction［J］.Arch Ophthalmol,1988,106(6):745-749.
［66］　HONG T,MITCHELL P,DE L T,ROCHTCHINA E,CUGATI S,WANG J J.Development and progression of diabetic retinopathy 12 months after phacoemulsification cataract surgery［J］.Ophthalmology,2009,116(8):1510-1514.
［67］　TAKAMURA Y,TOMOMATSU T,ARIMURA S,TOMOMATSU Y,MATSUMURA T,TAKIHARA Y,et al.Anterior capsule contraction and flare intensity in the early stages after cataract surgery in eyes with diabetic retinopathy［J］.J Cataract Refract Surg,2013,39(5):716-721.
［68］　ATTAS-FOX L,ZADOK D,GERBER Y,MORAD Y,ETING E,BENAMOU N,et al.Axial length measurement in eyes with diabetic macular edema: a-scan ultrasound versus IOL Master［J］.Ophthalmology,2007,114(8):1499-1504.
［69］　ROSE L T,MOSHEGOV C N.Comparison of the Zeiss IOLMaster and applanation A-scan ultrasound: biometry for intraocular lens calculation［J］.Clin Exp Ophthalmol,2003,31(2):121-124.
［70］　亚洲干眼协会中国分会,海峡两岸医药卫生交流协会眼科学专业委员会眼表与泪液病学组,中国医师协会眼科医师分会眼表与干眼学组.中国干眼专家共识：定义和分类（2020年）［J］.中华眼科杂志,2020,56(6):418-422.
Asian Dry Eye Association China Branch,Ophthalmology Group of Ophthalmology Professional Committee of Cross Strait Medical and Health Exchange Association,Ophthalmology Group of Ophthalmologist Branch of Chinese Medical Association.Consensus of Chinese dry eye experts:definition and classification (2020) ［J］.Chin J Ophthalmol,2020,56(6):418-422.
［71］　LJUBIMOV A V.Diabetic complications in the cornea［J］.Vision Res,2017,139:138-152.
［72］　XUE J,ZHANG B,DOU S,ZHOU Q,DING M,ZHOU M,et al.Revealing the angiopathy of lacrimal gland lesion in type 2 diabetes［J］.Front Physiol,2021,12:731234.
［73］　YU T,SHI W Y,SONG A P,GAO Y,DANG G F,DING G.Changes of meibomian glands in patients with type 2 diabetes mellitus［J］.Int J Ophthalmol,2016,9(12):1740-1744.
［74］　BARSEGIAN A,LEE J,MO S F,MCFARLANE S.Corneal neuropathy:an underrated manifestation of diabetes mellitus［J］.J Clin Endocrinol Diabetes,2018,2(1):JCED-J111.
［75］　中华医学会眼科学分会.中国神经营养性角膜炎诊断及治疗专家共识（2021年）［J］.中华眼科杂志,2021,57(2):90-94.
Ophthalmology Branch of Chinese Medical Association.Chinese expert consensus on diagnosis and treatment of neurotrophic keratitis (2021) ［J］.Chin J Ophthalmol,2021,57(2):90-94.
［76］　AL KAHTANI E S,KHANDEKAR R,AL-RUBEAAN K,YOUSSEF A M,IBRAHIM H M,AL-SHARQAWI A H.Assessment of the prevalence and risk factors of ophthalmoplegia among diabetic patients in a large national diabetes registry cohort［J］.BMC Ophthalmol,2016,16(1):118.
［77］　GRECO D,GAMBINA F,PISCIOTTA M,ABRIGNANI M,MAGGIO F.Clinical characteristics and associated comorbidities in diabetic patients with cranial nerve palsies［J］.J Endocrinol Invest,2012,35(2):146-149.
［78］　GRECO D,GAMBINA F,MAGGIO F.Ophthalmoplegia in diabetes mellitus:a retrospective study［J］.Acta Diabetol,2009,46(1):23-26.
［79］　WATANABE K,HAGURA R,AKANUMA Y,TAKASU T,KAJINUMA H,KUZUYA N,et al.Characteristics of cranial nerve palsies in diabetic patients［J］.Diabetes Res Clin Pract,1990,10(1):19-27.
［80］　RICHARDS B W,JONES F J,YOUNGE B R.Causes and prognosis in 4278 cases of paralysis of the oculomotor,trochlear,and abducens cranial nerves［J］.Am J Ophthalmol,1992,113(5):489-496.
［81］　雷涛,李正仪,刘轩,王润生,洪舟.眼外肌麻痹患者257例的临床特征及病因分析［J］.中华临床医师杂志(电子版),2013,(23):10549-10554.
LEI T,LI Z Y,LIU X,WANG R S,HONG Z.Clinical characteristics and etiological analysis of 257 patients with extraocular muscle paralysis ［J］.Chin J Clin (Electr Edit),2013,(23):10549-10554.
［82］　WILKER S C,RUCKER J C,NEWMAN N J,BIOUSSE V,TOMSAK R L.Pain in ischaemic ocular motor cranial nerve palsies［J］.Br J Ophthalmol,2009,93(12):1657-1659.
［83］　许纲,唐维桢,刘艺,吕中伟.糖尿病性动眼神经病变的治疗［J］.脑与神经疾病杂志,2012,20(1):69-73.
XU G,TANG W Z,LIU Y,L Z W.Treatment of diabetic oculomotor neuropathies［J］.J Brain Nerv Dis,2012,20(1):69-73.
［84］　JI M,QIN Y,ZI Y,WANG R,MENG H,YANG Z,et al.Acupuncture for ophthalmoplegia:protocol for a systematic review［J］.Medicine (Baltimore),2018,97(24):e11065.

相似文献/References:

[1]张 洁 孟小妹 张亦农.重度非增殖性与增殖性糖尿病性视网膜病变多焦视网膜电图一阶函数核的特征分析[J].眼科新进展,2008,28(9):000.
[2]陈娟,吕红彬. 抗VEGF药物在糖尿病性视网膜病变治疗中的应用[J].眼科新进展,2014,34(4):397.[doi:10.13389/j.cnki.rao.2014.0110]
[3]李婷婷,胡健艳,吴强.靶向G蛋白偶联受体91的小发夹RNA慢病毒载体的构建及功能初步检测[J].眼科新进展,2014,34(8):705.[doi:10.13389/j.cnki.rao.2014.0193]
　Li Ting-Ting,HU Jian-Yan,WU Qiang.Construction and identification of shRNA lentiviral vector of G protein-coupled receptor 91[J].Recent Advances in Ophthalmology,2014,34(4):705.[doi:10.13389/j.cnki.rao.2014.0193]
[4]陈明,刘志谦,段志辉,等.玻璃体切割联合保留前囊膜的晶状体切除治疗糖尿病性视网膜病变[J].眼科新进展,2014,34(10):956.[doi:10.13389/j.cnki.rao.2014.0265]
[5]陈小红,王云鹏,陈梅珠. VEGF在糖尿病性视网膜病变发病机制中的作用及抗VEGF治疗新进展[J].眼科新进展,2015,35(7):692.[doi:10.13389/j.cnki.rao.2015.0190]
　CHEN Xiao-Hong,WANG Yun-Peng,CHEN Mei-Zhu. Role of VEGF in pathogenesis of diabetic retinopathy and anti-VEGF therapy[J].Recent Advances in Ophthalmology,2015,35(4):692.[doi:10.13389/j.cnki.rao.2015.0190]
[6]向小红,吕红彬.雌激素与糖尿病性视网膜病变的研究进展[J].眼科新进展,2017,37(5):496.[doi:10.13389/j.cnki.rao.2017.0126]
　XIANG Xiao-Hong,LV Hong-Bin.Recent advances in estrogen and diabetic retinopathy[J].Recent Advances in Ophthalmology,2017,37(4):496.[doi:10.13389/j.cnki.rao.2017.0126]
[7]张鹏飞,张杰,高荣玉,等.玻璃体内注射血管内皮生长因子（VEGF）抑制剂治疗糖尿病视网膜病变患者的疗效[J].眼科新进展,2018,38(10):977.[doi:10.13389/j.cnki.rao.2018.0231]
　ZHANG Peng-Fei,ZHANG Jie,GAO Rong-Yu,et al.The efficacy of intravitreal injection of vascular endothelial growth factor （VEGF） inhibitors in patients with diabetic retinopathy[J].Recent Advances in Ophthalmology,2018,38(4):977.[doi:10.13389/j.cnki.rao.2018.0231]
[8]许冬,李浩,周利晓,等.基于卷积神经网络UNet构建糖尿病性黄斑水肿自动识别模型[J].眼科新进展,2020,40(4):357.[doi:10.13389/j.cnki.rao.2020.0082]
　XU Dong,LI Hao,ZHOU Lixiao,et al.Model of automatic identification of diabetic macular edema via convolutional neural networks UNet[J].Recent Advances in Ophthalmology,2020,40(4):357.[doi:10.13389/j.cnki.rao.2020.0082]
[9]李莹莹,蔺晓慧.糖尿病性视网膜病变患者血清中脂肪细胞因子的表达及其影响因素分析[J].眼科新进展,2021,41(1):057.[doi:10.13389/j.cnki.rao.2021.0012]
　LI Yingying,LIN Xiaohui.Expression of adipocytokines in the serum of patients with diabetic retinopathy and its factors[J].Recent Advances in Ophthalmology,2021,41(4):057.[doi:10.13389/j.cnki.rao.2021.0012]
[10]赵立宇,姜茂华,杨芳,等.糖尿病性视网膜病变患者常规全视网膜光凝后黄斑中心凹下脉络膜厚度变化的荟萃分析[J].眼科新进展,2022,42(2):136.[doi:10.13389/j.cnki.rao.2022.0028]
　ZHAO Liyu,JIANG Maohua,YANG Fang,et al.A meta-analysis of changes in the subfoveal choroidal thickness in diabetic retinopathy patients after conventional panretinal photocoagulation[J].Recent Advances in Ophthalmology,2022,42(4):136.[doi:10.13389/j.cnki.rao.2022.0028]

备注/Memo

备注/Memo:
国家自然科学基金（编号：82171072）；广东省自然科学基金（编号：2019A1515010697，2021A1515010921）；广州市科技计划项目（编号：202002030400）；白求恩·朗沐中青年眼科科研基金（编号：BJ-LM2019004J）
更新日期/Last Update: 2022-04-05